Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Total Equity: HK$6,173 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06990 Sichuan Kelun-Biotech Biopharmaceutical Co Ltd HKSE:06990
44 GF Score
Price HK$523.00
GF Value HK$254.91
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sichuan Kelun-Biotech Biopharmaceutical Co Total Equity?

Sichuan Kelun-Biotech Biopharmaceutical Co HKSE:06990 -2.79% 44 Total Equity is HK$6,173 Mil as of Jun. 2026. GuruFocus rates HKSE:06990 with a GF Score™ of 44/100 and a GF Value™ of HK$254.91 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Sichuan Kelun-Biotech Biopharmaceutical Co's total equity for the quarter that ended in Jun. 2026 was HK$6,173 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Sichuan Kelun-Biotech Biopharmaceutical Co Total Equity Historical Data

* Premium members only.

The historical data trend for Sichuan Kelun-Biotech Biopharmaceutical Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sichuan Kelun-Biotech Biopharmaceutical Co Total Equity Chart

Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
-3,237.35 -3,602.73 2,547.96 3,532.57 5,376.78

Sichuan Kelun-Biotech Biopharmaceutical Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,454.83 3,532.57 5,480.91 5,376.78 6,173.24
HKSE:06990
44GF Score
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd HKSE:06990
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sichuan Kelun-Biotech Biopharmaceutical Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Sichuan Kelun-Biotech Biopharmaceutical Co's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=6615.696-1238.922
=5,377

Sichuan Kelun-Biotech Biopharmaceutical Co's Total Equity for the quarter that ended in Jun. 2026 is calculated as

Total Equity=Total Assets(Q: Jun. 2026 )-Total Liabilities(Q: Jun. 2026 )
=7312.461-1139.222
=6,173

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of HK$6,173 Mil mean?
Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) has a Total Equity of HK$6,173 Mil as of Jun. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Sichuan Kelun-Biotech Biopharmaceutical Co and its competitors.
Is Sichuan Kelun-Biotech Biopharmaceutical Co's Total Equity too high?
Sichuan Kelun-Biotech Biopharmaceutical Co's current Total Equity is HK$6,173 Mil. Overall, Sichuan Kelun-Biotech Biopharmaceutical Co has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sichuan Kelun-Biotech Biopharmaceutical Co's Total Equity compare to VRTX and REGN?
Sichuan Kelun-Biotech Biopharmaceutical Co's Total Equity of HK$6,173 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Sichuan Kelun-Biotech Biopharmaceutical Co and its competitors. Sichuan Kelun-Biotech Biopharmaceutical Co's current Total Equity is HK$6,173 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sichuan Kelun-Biotech Biopharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$254.91, compared to a current price of HK$523.00 — trading 105.2% above its estimated fair value. The current Total Equity is HK$6,173 Mil. Sichuan Kelun-Biotech Biopharmaceutical Co's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990), the current Total Equity is HK$6,173 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Overvalued in 2026?

Based on GuruFocus' analysis, Sichuan Kelun-Biotech Biopharmaceutical Co stock appears to be overvalued. The current stock price of HK$523.00 is trading 105.2% above its estimated GF Value™ of HK$254.91. GuruFocus considers Sichuan Kelun-Biotech Biopharmaceutical Co to be Significantly Overvalued.

Key valuation signals for HKSE:06990:

  • Total Equity: HK$6,173 Mil
  • GF Value™: HK$254.91 vs. price of HK$523.00 (105.2% above fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the HKSE:06990 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sichuan Kelun-Biotech Biopharmaceutical Co Business Description

Address No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang, Sichuan, Chengdu, CHN
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a biopharmaceutical company committed to the R&D, manufacturing, and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population. Currently, the company has two ADC drugs as Core Products, namely, sac-TMT and trastuzumab botidotin.
44GF Score

Get the complete analysis for HKSE:06990

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$523.00
Price
HK$254.91
GF Value